Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

tions, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that survival trends will not be replicated in larger trials and the risk that the company will experience delays in patient enrollment. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregri
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the ... for 2014. The awards program, created in 2000, is ... in the country. The program is a public/private partnership ... and Economic Development, the Pennsylvania State Council of the ... Business Journal. , Charlie Wilson, Vice President ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Helen ... home in Woodland Hills, California after an 8 year ... away on Christmas Eve evening in her home in ... aggressive metastatic breast cancer. , As ... over forty years, she pioneered and championed many of ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- Overeating is common during ... eat in moderation, an expert says. "Don,t arrive at ... calories if you know you,ll be attending a party, but ... Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount Kisco, ... to eat healthy during the day and even to have ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , ( ) , , , ... N.J., Aug. 6 Smart Balance, Inc. (Nasdaq: SMBL ) today announced its ... of $58.2 million, an increase of 21.2% versus year ago, and earnings per share of ... The second quarter net sales increase versus 2008 was due to a 13% ...
... Lifestyle changes up the odds for Cubans, Puerto Ricans, Mexicans, ... Hispanics who move to the United States, the good life ... their risk for cancer by 40 percent. , Living the ... University of Miami Miller School of Medicine. , Of three ...
... , NASHVILLE, Tenn. and GLEN ... find that 76 percent of surveyed pharmacy directors say ... will have only one preferred biologic for all immune ... ulcerative colitis. According to the new Formulary Forum report ...
... , , REDWOOD CITY, ... ) today announced that Kim Popovits, Genomic Health,s Chief Executive Officer, ... in Boston, on Thursday, August 13 at 1:30 p.m. ET. , ... webcast of the presentation, visit the Investor Relations section of Genomic ...
... , , HOUSTON, ... first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a ... cancer. The disease-specific trial is being conducted under a Bellicum Investigational ... anticipates reporting initial results of the study in 2010. , ...
... KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir Optical ... issue its second quarter of 2009 earnings results on Thursday, August 13(th), ... 11:00 A.M. EDT that morning. , , The ... live, please go to www.kcsa.com approximately five minutes ...
Cached Medicine News:Health News:Smart Balance Announces 2009 Second Quarter Results 2Health News:Smart Balance Announces 2009 Second Quarter Results 3Health News:Smart Balance Announces 2009 Second Quarter Results 4Health News:Smart Balance Announces 2009 Second Quarter Results 5Health News:Smart Balance Announces 2009 Second Quarter Results 6Health News:Smart Balance Announces 2009 Second Quarter Results 7Health News:Smart Balance Announces 2009 Second Quarter Results 8Health News:Smart Balance Announces 2009 Second Quarter Results 9Health News:Smart Balance Announces 2009 Second Quarter Results 10Health News:Living in U.S. May Raise Hispanics' Cancer Risk 2Health News:Living in U.S. May Raise Hispanics' Cancer Risk 3Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2
(Date:12/24/2014)... , Dec. 24, 2014  Commonwealth Cornerstone Group (CCG) ... Tax Credits transaction on Tuesday to help fund the expansion ... (PHN) in Sharon . ... Pennsylvania . It is the largest employer ... more than 150 people on staff. Currently, PHN ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... 10 A recent national survey of 505 pharmacists found ... for a patient to seek treatment early to help shorten ... percent of pharmacists say most patients should purchase over-the-counter (OTC) ... while only 26 percent of their patients take this proactive ...
... Nov. 10 Reportlinker.com announces that a ... its catalogue. , Injectable Drug ... , http://www.reportlinker.com/p0158352/Injectable-Drug-Delivery-Market-Impact-and-Industry-Trends.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... grows, companies are increasingly looking towards the ...
Cached Medicine Technology:Pharmacists Report Patients do not Treat Cold and Flu Symptoms Early Enough, New Survey Shows 2Pharmacists Report Patients do not Treat Cold and Flu Symptoms Early Enough, New Survey Shows 3Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 2Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 3Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 4Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 5Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 6
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
Medicine Products: